Added to YB: 2024-04-23
Pitch date: 2024-04-08
BIIB [bullish]
Biogen Inc.
-15.94%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Market Cap
$27.5B
Pitch Price
$205.02
Price Target
326.00 (+89%)
Dividend
N/A
EV/EBITDA
8.03
P/E
21.34
EV/Sales
3.03
Sector
Biotechnology
Category
turnaround
Show full summary:
RBC Capital Markets Investment Thesis: Biogen Inc.
BIIB: Alzheimer's drug potential may drive upside despite MS headwinds. Lecanemab launch key; pipeline has promise but challenges remain. $326 PT on DCF (9.5% discount, 3% terminal growth). Catalysts: Leqembi & Skyclarys launch trends, SLE drug data. Risks: MS pricing pressure, Alzheimer's reimbursement.
Read full article (2 min)